Core Insights - Fresenius Medical Care AG & Co. KGaA has received a consensus recommendation of "Hold" from seven research firms, with varying ratings including three sell, one hold, two buy, and one strong buy [2] - The average twelve-month price objective among brokers is $27.80 [2] Analyst Ratings - Zacks Research upgraded the stock from "hold" to "strong-buy" on October 6 [3] - Morgan Stanley maintained an "underweight" rating on August 12 [3] - UBS Group downgraded the stock from "sell" to "underperform" on October 15 [3] - Bank of America also downgraded the stock from "neutral" to "underperform" on October 15 [3] - Weiss Ratings upgraded the stock from "hold (c+)" to "buy (b-)" on October 8 [3] Institutional Investment Activity - Wayfinding Financial LLC purchased a new stake worth approximately $25,000 in Q1 [4] - TD Waterhouse Canada Inc. acquired a new stake worth about $36,000 in Q2 [4] - Brooklyn Investment Group increased its position by 424.5% in Q1, now owning 1,285 shares valued at $32,000 [4] - Atlantic Union Bankshares Corp bought a new stake worth about $43,000 in Q2 [4] - Hantz Financial Services Inc. grew its position by 568.5% in Q2, now owning 2,079 shares valued at $59,000 [4] - Institutional investors own 8.37% of the stock [4] Financial Performance - The stock opened at $26.83, with a market cap of $15.74 billion [6] - The company reported an EPS of $0.52 for the last quarter, exceeding the consensus estimate of $0.50 by $0.02 [7] - Revenue for the quarter was $5.54 billion, surpassing the consensus estimate of $5 billion [7] - The company has a net margin of 3.39% and a return on equity of 6.75% [7] - Analysts expect an EPS of 1.51 for the current fiscal year [7] Company Overview - Fresenius Medical Care AG & Co. KGaA provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally [9] - The company operates outpatient dialysis clinics and offers materials, training, and patient support services [9]